



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,217	07/11/2003	Akio Matsuda	1254-0229P	6837

2292 7590 07/11/2005

BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

EXAMINER

BORIN, MICHAEL L

ART UNIT PAPER NUMBER

1631

DATE MAILED: 07/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/617,217

Applicant(s)

MATSUDA ET AL.

Examiner

Michael Borin

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-45 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-45 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

Part III DETAILED ACTION

Claims 1-45 are currently pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claim 1,2,8, drawn to a purified polypeptide encoded by a polynucleotide from an EST library, classified in class 530, subclass 300.
- II. Claims 3-7,9-11,13, drawn to isolated nucleic acid, their homologs, expression vectors and cells comprising the vector, classified in class 536, subclass 23.1 and class 935, subclass 66.
- III. Claim 12, drawn to cell membrane.
- IV. Claim 14, drawn to polynucleotide-based methods of diagnosing a disease, classified in class 435, subclass 6.
- V. Claim 15, drawn to polynucleotide-based methods of screening of inhibitors or promoters NF-kB activation compounds , classified in class 435, subclass 6.
- VI. Claim 16, drawn to method for producing pharmaceutical composition, classified in class 435, subclass 325.
- VII. Claim 17, drawn to kit, classified in class 435, subclass 810.

Art Unit: 1631

VIII. Claim 18-20, drawn to an antibody to a polypeptide, classified in class 530, subclass 388.1, and claims 35,40, drawn to pharmaceutical composition thereof.

IX. Claim 21, drawn to antisense to polynucleotide of Group II, class 536, subclass 23.1, and claims 36,40, drawn to pharmaceutical composition thereof.

X. Claims 22,37, drawn to ribozyme.

XI. Claims 30,31, drawn to method of treatment using compound identified by method of Group V, classified in class 514, in general.

The group will be subject to further restriction, if elected.

XII. Claims 32,33, drawn to pharmaceutical composition produced by method of Group VI, classified in class 514, in general.

XIII. Claim 34, drawn to method of treating inflammation using pharmaceutical composition produced by method of Group VI, classified in class 514, in general.

XIV. Claim 41, drawn to method of obtaining a novel gene.

XV. Claim 42, drawn to computer medium storing sequence of polypeptide or polynucleotide, classified in class 550, subclass 170.

XVI. Claim 43, drawn to method for calculating nucleotide identity, classified in class 702, subclass 19.

XVII. Claim 44, drawn to (unidentified) substrate to polynucleotides of Group II.

XVIII. Claim 45, drawn to (unidentified) substrate to polypeptides of Group I.

XIX. Claims 23,24,38,39, drawn to double-stranded nucleic acids, classified in class 536, subclass 23.1.

XX. Claims 25-29,38,39, drawn to double-stranded nucleic acids, classified in class 536, subclass 23.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups I, II, III, VIII, IX, X, XII, XIX,XX are structurally and functionally different products which are made by different methods and have different uses. The examination of the Groups will require different searches of the US Patents and scientific literature and would require consideration of different patentability issues. With respect to nucleic acids of Groups II, XIX,XX, the products do not have common core structure as claimed – the term “corresponding” in claim 23 is indefinite and it is unclear what is being addressed in the claims.

Inventions I and II are separate and distinct because the inventions are directed to different chemical types regarding the critical limitations therein. For Group I, the critical feature is a polypeptide whereas for Group II the critical feature is a polynucleotide. It is acknowledged that various processing steps may cause a polypeptide of group II to be directed as to its synthesis by a polynucleotide, however, the completely separate chemical types of the inventions of Groups I and II supports the undue search burden if both were examined together. Additionally, polypeptides have been most commonly, albeit not always, separately characterized and published in the Biochemical literature, thus significantly adding to the search burden if examiner together, as compared to being searched separately. Also, it is pointed out that processing that may connect two groups does not prevent them from being viewed as

distinct, because enough processing can result in producing any composition from any other composition if the processing is not so limited to additions, subtractions, enzyme actions, etc.

Inventions I and VIII are separate and distinct as the polypeptides of Invention I are structurally and biochemically different than the antibodies of Invention VIII. While the antibodies may bind to the polypeptides of Invention I, the biochemical activities of each Invention are quite different, requiring differing methods and areas of search, which would impose an undue burden upon the examiner.

Inventions II and VIII are separate and distinct, as the claims of Invention II are drawn to polynucleotides, while the claim of group VIII is drawn to an antibody. These are differing biochemical entities having differing biochemical properties, structures and effects. Invention VIII would require searching in areas unrelated to polynucleotides, and as such, would require an undue burden on the examiner if not restricted.

The kit of Group VII is unrelated to product of Group II as it contains a gene, rather than polynucleotides of Group II.

Substrates of groups XVII, VIII have no structural characteristics and are considered to be structurally unrelated to other claimed products as well as to each other.

Inventions II and IV-VI are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Art Unit: 1631

process of using that product (MPEP . 806.05(h)). In the instant case, methods IV-VI are alternate methods of using the compound of Group II

The methods of groups IV-VI,XI,XIII,XIV,XVI are related as independent methods which differ in the method objectives, with differing steps using differing reagents and materials, to differing ends.

For example, inventions IV and XI are separate and distinct as each method comprises differing steps using differing reagents and materials, to differing ends. Invention IV ends with diagnosing a disease determining presence of a mutation in polynucleotide, while Invention XI ends with the treatment of a disease using a compound of unrelated structure. As such the Inventions would require search in separate and non-overlapping areas, imposing an undue search burden upon the examiner if not restricted.

Inventions of Groups XVI and I or II are separate and patentably distinct, as a nucleotide or peptide sequence can be recorded on any type of medium other than computer readable (e.g., on paper), and because a computer readable medium can contain any type of information, other than the sequence of polynucleotides or polypeptides of Groups I or II.

Sequence Election Requirement Applicable to All Groups

In addition, each Group detailed above reads on a plurality of independent and/or patentably distinct sequences. Each peptide or nucleic acid sequence is independent and/or patentably distinct because they are unrelated compounds, there is no disclosed core structure required for a common utility, and because each of these compounds possess different structure and/or physico-chemical properties, and/or capable of separate manufacture and/or use. **For an elected Group the Applicants must further elect a single amino acid or nucleic acid sequence.**

MPEP 803.04 states:

Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Examination will be restricted only to a Group drawn to elected sequences.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and because of their recognized divergent subject matter, and the necessity for non-coextensive literature searches restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph.D., can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

 Michael Borin, Ph.D.
Primary Examiner
Art Unit 1631